64 results
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc
9 Feb 24
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
12:34pm
of physical or mental illness or injury and where it would cause undue hardship to the Company to accommodate.
(iv)
“Good Reason” means the occurrence
8-K
EX-10.2
INM
InMed Pharmaceuticals Inc
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
3:47pm
that if the Consultant breaches any of the Consultant’s obligations under this Agreement, that breach may give rise to irreparable injury
8-K
EX-10.1
3gqh27 srshcbi6lqtf
19 Jul 22
InMed Announces Appointment of Chief Operating Officer
7:43pm
424B5
7vpah9g14r
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
irrrla l5esm
25 Apr 22
Prospectus supplement
5:02pm
424B3
fp24mbqd3w9 rtwl8
7 Apr 22
Prospectus supplement
4:46pm
S-3
0ydffmv3xr86df0e
4 Feb 22
Shelf registration
4:36pm
8-K/A
EX-99.2
9rb0dxhkn10prl3
22 Dec 21
Audited Financial Statements
12:00am
8-K/A
EX-99.1
yjsmytlyf2mo37d
22 Dec 21
Audited Financial Statements
12:00am
8-K
EX-2.1
yf3b2arnf7fmqh4ncbz
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
8-K
EX-99.1
f6zo qe01
30 Sep 21
Regulation FD Disclosure
1:30pm
10-K
EX-2.1
q0ejnt1loxe9knl4vzs
24 Sep 21
Annual report
7:31am
10-K
vuzcp0l9ar36nflzo
24 Sep 21
Annual report
7:31am
424B3
3zw3tjfo en6zz
22 Jul 21
Prospectus supplement
10:27am